TRLS.L
Trellus Health plc [TRLS.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
TRLS.L Stock Summary
Top 10 Correlated ETFs
TRLS.L
Top 10 Correlated Stocks
TRLS.L
In the News
TRLS.L Financial details
Company Rating
Neutral
Market Cap
3.07M
Income
-7.54M
Revenue
22K
Book val./share
0.14
Cash/share
0.1
Dividend
-
Dividend %
-
Employees
31
Optionable
No
Shortable
Yes
Earnings
21 May 2024
P/E
-1.26
Forward P/E
-
PEG
-3.14
P/S
616.8
P/B
0.44
P/C
19.4
P/FCF
-0.96
Quick Ratio
23.22
Current Ratio
23.56
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.05
EPS next Y
-
EPS next Q
-
EPS this Y
21.65%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-32.17%
SMA50
-58.99%
SMA100
-58.46%
Inst Own
-
Inst Trans
-
ROA
-34%
ROE
-29%
ROC
-0.35%
Gross Margin
100%
Oper. Margin
-48944%
Profit Margin
-48944%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.85-9.65
52W High
-78.44%
52W Low
+94%
RSI
23.65
Rel Volume
0.63
Avg Volume
170.32K
Volume
106.7K
Perf Week
-3%
Perf Month
-40.31%
Perf Quarter
-63.05%
Perf Half Y
-64.73%
-
-
-
-
Beta
0.102
-
-
Volatility
0.11%, 0.46%
Prev Close
10.86%
Price
1.94
Change
10.86%
TRLS.L Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | |
| Net income per share | -0.02 | -0.04 | -0.05 | |
| Operating cash flow per share | -0.02 | -0.04 | -0.05 | |
| Free cash flow per share | -0.02 | -0.06 | -0.07 | |
| Cash per share | 0.04 | 0.24 | 0.12 | |
| Book value per share | 0.05 | 0.27 | 0.16 | |
| Tangible book value per share | 0.04 | 0.24 | 0.12 | |
| Share holders equity per share | 0.05 | 0.27 | 0.16 | |
| Interest debt per share | 0 | 0 | 0 | |
| Market cap | 81.33M | 84.46M | 19.54M | |
| Enterprise value | 77.64M | 52.48M | 457.51K | |
| P/E ratio | -53.37 | -14.31 | -2.22 | |
| Price to sales ratio | 0 | 3.38K | 1.09K | |
| POCF ratio | -62.56 | -17.7 | -2.27 | |
| PFCF ratio | -61.43 | -9.95 | -1.7 | |
| P/B Ratio | 19.15 | 2.39 | 0.78 | |
| PTB ratio | 19.15 | 2.39 | 0.78 | |
| EV to sales | 0 | 2.1K | 25.42 | |
| Enterprise value over EBITDA | -51.01 | -8.94 | -0.06 | |
| EV to operating cash flow | -59.73 | -11 | -0.05 | |
| EV to free cash flow | -58.64 | -6.18 | -0.04 | |
| Earnings yield | -0.02 | -0.07 | -0.45 | |
| Free cash flow yield | -0.02 | -0.1 | -0.59 | |
| Debt to equity | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | |
| Net debt to EBITDA | 2.42 | 5.45 | 2.31 | |
| Current ratio | 30.29 | 21.32 | 23.56 | |
| Interest coverage | 0 | 0 | 0 | |
| Income quality | 0.85 | 0.81 | 0.98 | |
| Dividend Yield | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 237.08 | 490.44 | |
| Research and developement to revenue | 0 | 0.88 | 32.94 | |
| Intangibles to total assets | 0.15 | 0.12 | 0.25 | |
| Capex to operating cash flow | 0.02 | 0.78 | 0.34 | |
| Capex to revenue | 0 | -148.84 | -161.56 | |
| Capex to depreciation | -12 | -116.28 | -5.43 | |
| Stock based compensation to revenue | 0 | 5.56 | 3.44 | |
| Graham number | 0.14 | 0.52 | 0.44 | |
| ROIC | -0.36 | -0.17 | -0.35 | |
| Return on tangible assets | -0.41 | -0.18 | -0.45 | |
| Graham Net | 0.04 | 0.23 | 0.11 | |
| Working capital | 3.57M | 30.91M | 18.55M | |
| Tangible asset value | 3.58M | 31M | 18.6M | |
| Net current asset value | 3.57M | 30.91M | 18.55M | |
| Invested capital | 0 | 0 | 0 | |
| Average receivables | 0 | 12.5K | 12.5K | |
| Average payables | 0 | 797K | 1.17M | |
| Average inventory | 0 | 218K | 218K | |
| Days sales outstanding | 0 | 365 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | |
| Receivables turnover | 0 | 1 | 0 | |
| Payables turnover | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | |
| ROE | -0.36 | -0.17 | -0.35 | |
| Capex per share | 0 | -0.03 | -0.02 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | |
| Operating cash flow per share | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | |
| Free cash flow per share | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | |
| Cash per share | 0.15 | 0.12 | 0.12 | 0.1 | 0.1 | |
| Book value per share | 0.18 | 0.16 | 0.16 | 0.14 | 0.14 | |
| Tangible book value per share | 0.14 | 0.12 | 0.12 | 0.1 | 0.1 | |
| Share holders equity per share | 0.18 | 0.16 | 0.16 | 0.14 | 0.14 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 27.35M | 13.08M | 19.54M | 13.01M | 12.21M | |
| Enterprise value | 3.38M | -6.01M | 458.12K | -2.81M | -3.6M | |
| P/E ratio | -2.82 | -1.65 | -2.46 | -1.82 | -1.71 | |
| Price to sales ratio | 5.47K | 3.27K | 4.89K | 1.86K | 1.74K | |
| POCF ratio | -11.56 | -6.73 | -10.05 | -8.35 | -7.84 | |
| PFCF ratio | -11.56 | -6.73 | -10.05 | -8.35 | -7.84 | |
| P/B Ratio | 0.94 | 0.52 | 0.78 | 0.58 | 0.55 | |
| PTB ratio | 0.94 | 0.52 | 0.78 | 0.58 | 0.55 | |
| EV to sales | 675.45 | -1.5K | 114.53 | -400.84 | -514.3 | |
| Enterprise value over EBITDA | -1.4 | 3.2 | -0.24 | 1.51 | 1.94 | |
| EV to operating cash flow | -1.43 | 3.09 | -0.24 | 1.8 | 2.31 | |
| EV to free cash flow | -1.43 | 3.09 | -0.24 | 1.8 | 2.31 | |
| Earnings yield | -0.09 | -0.15 | -0.1 | -0.14 | -0.15 | |
| Free cash flow yield | -0.09 | -0.15 | -0.1 | -0.12 | -0.13 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 9.93 | 10.18 | 10.01 | 8.51 | 8.51 | |
| Current ratio | 17.11 | 23.56 | 23.56 | 34.63 | 34.63 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 0.98 | 0.98 | 0.98 | 0.87 | 0.87 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 485 | 167.13 | 167.13 | 268.79 | 268.79 | |
| Research and developement to revenue | 0 | 74.13 | 74.13 | 0 | 0 | |
| Intangibles to total assets | 0.19 | 0.25 | 0.25 | 0.3 | 0.3 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0.9 | 6.63 | 6.63 | 1.36 | 1.36 | |
| Graham number | 0.25 | 0.21 | 0.21 | 0.19 | 0.19 | |
| ROIC | -0.08 | -0.08 | -0.08 | -0.08 | -0.08 | |
| Return on tangible assets | -0.1 | -0.1 | -0.1 | -0.11 | -0.11 | |
| Graham Net | 0.14 | 0.11 | 0.11 | 0.1 | 0.1 | |
| Working capital | 23.02M | 18.55M | 18.55M | 15.54M | 15.54M | |
| Tangible asset value | 23.09M | 18.6M | 18.6M | 15.58M | 15.58M | |
| Net current asset value | 23.02M | 18.55M | 18.55M | 15.54M | 15.54M | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 240.5K | 0 | 93.5K | 187K | |
| Average payables | 0 | 945.5K | 642K | 642K | 462K | |
| Average inventory | 0 | -240.5K | 0 | 0 | 0 | |
| Days sales outstanding | 8.66K | 0 | 0 | 2.4K | 2.4K | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0.01 | 0 | 0 | 0.04 | 0.04 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.08 | -0.08 | -0.08 | -0.08 | -0.08 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
TRLS.L Frequently Asked Questions
What is Trellus Health plc stock symbol ?
Trellus Health plc is a US stock , located in White plains of Ny and trading under the symbol TRLS.L
What is Trellus Health plc stock quote today ?
Trellus Health plc stock price is $1.94 today.
Is Trellus Health plc stock public?
Yes, Trellus Health plc is a publicly traded company.
Company Profile
- Volume Average 170.32K
- Market Capitalization 3.07M
- Employee 31
- CEO Dr. Marla Cindy Dubinsky M.D.
- Headquarters White Plains,NY,US
- IPO Date 2021-05-31
-
Website
https://www.trellushealth.com 
Trellus Health plc provides digital chronic condition management solutions for employers and health plans. The company offers TrellusElevate, a proprietary HIPAA-compliant technology platform to coordinate and deliver personalized care remotely through telemedicine. Its platform provides patients with access to a care team, educational content resources, and remote monitoring capabilities for the treatment of inflammatory bowel diseases, which include the chronic incurable conditions of Crohn's Disease and ulcerative colitis. The company was founded in 2020 and is headquartered in White Plains, New York.
